CD19 and neoplasm: For instance, in CAR-T therapies targeting CD19, such as those used for B-cell malignancies, some tumor cells may undergo genetic alterations that result in the deletion or mutation of the CD19 gene, leading to the absence of the CD19 protein on their surface.